Astrazeneca, Bristol Myers Squibb Discuss Potential Merger
Astrazeneca and Bristol Myers Squibb in talks for potential combination
AZN BMY Astrazeneca (AZN) and Bristol Myers Squibb (BMY) have held preliminary discussions about a potential combination that would create one of the world's largest Pharmaceutical companies. by the Financial Times.
Astrazeneca (AZN) is valued at about £196B ($264B), while Bristol Myers Squibb (BMY) has a market capitalization of roughly $133B Link To Story.com